News Nation on MSN4h
AbbVie enters into almost $2B contract with Gubra for obsesity drug
Bloomberg reports the obesity drug market is expected to reach as much as $130 billion in annual sales by 2030.
BioPharma Dive2d
AbbVie gets into obesity with $350M deal for once-weekly shot
A licensing deal with Denmark’s Gubra gives the immunology giant control of an experimental therapy that could compete with ...
STAT9h
How the race for the next obesity drug is shaping up
While some drugs have fallen off, more have been added: AbbVie recently jumped into the obesity craze by licensing an ...
FierceBiotech2d
AbbVie pays Gubra $350M to make late play for obesity space
AbbVie is paying $350 million to join the obesity race. The outlay, plus up to $1.875 billion in milestones, has landed the ...
MedCity News3d
AbbVie Enters Obesity Field, Paying $350M for Amylin Receptor Agonist Already in the Clinic
AbbVie is joining the chase for new obesity drugs, but rather than getting a me-too GLP-1 drug, the pharmaceutical giant is landing rights to a clinical-stage molecule that goes after two novel ...
BioSpace17h
Tariff Threat Continues, More Meetings Cancelled, AbbVie Makes Obesity Play, More
Pfizer reacts to Donald Trump’s tariff threats on big pharma, another regulatory meeting is canceled under RFK Jr., AbbVie ...
AbbVie price target raised to $223 from $200 at BofA
BofA raised the firm’s price target on AbbVie (ABBV) to $223 from $200 and keeps a Neutral rating on the shares after the company and Gubra ...